Cost-utility analysis a case study of a quadrivalent human papillomavirus vaccine

Pharmacoeconomics: From Theory to Practice

Volumn , Issue , 2016, Pages 119-132

  Dasbach, Erik J ^a   Insinga, Ralph P ^a   Elbasha, Elamin H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855991722     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (34)

1. NICE. NHS. National Institute for Clinical Excellence. Guide to the methods of technology appraisal Issue date: June 2008. http://www.nice.org.uk/media/B52/A7/ TAMethodsGuideUpdatedJune2008.pdf accessed July 23, 2008.
2. Devlin N, Parkin D. 2004. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 13(5):437-52.
3. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. 2004. Use of cost-effectiveness analysis in health-care resource allocation decision-making: How are cost-effectiveness thresholds expected to emerge? Value in Health 7(5):518-28.
4. Grosse SD. 2008. Assessing cost-effectiveness in healthcare: History of the $50,000 per QALY threshold. Expert Rev. Pharmacoeconomics Res 8:165-178. 2008.
5. WHO. World Health Organization. Choosing Interventions that are Cost Effective (WHO-CHOICE) Tables of costs and prices used in WHO-CHOICE analysis. http://www.who.int/ choice/costs/CER_levels/en/index.html: accessed July 28, 2008.
6. Center on the Evaluation of Value and Risk in Health (2008). The cost-effectiveness analysis registry, Tufts-New England Medical Center, ICRHPS. http://www.tufts-nemc. org/cearegistry/data/docs/PhaseIIIACompleteLeagueTable.pdf accessed July 28, 2008.
7. ACIP. ACIP Record of the Proceedings June 29-30, 2006. http://www.cdc.gov/vaccines/ recs/acip/downloads/min-jun06.pdf: accessed July 30, 2008.
8. Markowitz LE, Dunne EF, Saraiya M et al. Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007. 56:1-24. 2007.
9. Elbasha EH, Dasbach EJ, Insinga RP. 2007. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 13(1):28-41.
10. Elbasha EH, Dasbach EJ, Insinga RP. 2008. A multi-type HPV transmission model: Assessing the epidemiologic and economic impact of a quadrivalent HPV vaccine. Bull Math Biol 70:2126-2176.
11. Brisson M, Edmunds WJ. 2003. Economic evaluation of vaccination programs: The impact of herd-immunity. Med Decis Making 23(1):76-82.
12. Hewitt M et al. 2004. Cervical cancer screening among U.S. women: Analyses of the 2000 National Health Interview Survey. Prev Med 39(2):270-8.
13. Insinga RP et al. 2004. Pap screening in a U.S. health plan. Cancer Epidem Biomarkers Prev 13(3):355-60.
14. Bigras G, de Marval F. 2005. The probability for a Pap test to be abnormal is directly proportional to HPV viral load: Results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women. Br J Cancer 93(5):575-81.
15. Merck & Co., Inc. GARDASIL Prescribing Information. www.gardasil.com/downloads/ gardasil_pi.pdf: accessed July 30, 2008. 2007.
16. Stratton K. Committee to Study Priorities for Vaccine Development. Institute of Medicine. Vaccines for the 21st century: A tool for decisionmaking. Appendix 11. Human Papillomavirus pp. 213-222. Washington DC: National Academy Press. 2000. http://www.iom.edu/report.asp?id=5648 accessed July 30, 2008.
17. Goldie S, Grima D, Kohli M, Weinstein M, Wright T, Franco E. 2003. A comprehensive natural history model of human papillomavirus (HPV) infection and cervical cancer: Potential impact of an HPV 16/18 vaccine. Value in Health 5(6):576.
18. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E. 2004. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96(8):604-15.
19. Sanders GD, Taira AV. 2003. Cost effectiveness of a potential vaccine for Human papillomavirus. Emerg Infect Dis 9(1):37-48.
20. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. 2008. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 14(2):244-51.
21. Kim JJ, Wright TC, Goldie SJ. 2002. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 287(18):2382-90.
22. Insinga RP, Dasbach EJ, Myers E. 2003. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 36(11):1397-403.
23. Froberg DG, Kane RL. 1989. Methodology for measuring health-state preferences. 2. Scaling methods. J Clin Epidemiol 42(5):459-71.
24. Neumann PJ, Goldie SJ, Weinstein MC. 2000. Preference-based measures in economic evaluation in health care. Annu Rev Public Health 21:587-611.
25. Dasbach EJ, Teusch, SM. Quality of life. In Dasbach EJ, Haddix, AC, Corso, PS, Eds. Prevention effectiveness: A guide to decision analysis and economic evaluation. Second Edition. 2003. NYC, Oxford University Press, 2003.
26. Myers ER, Green S, Lipkus I. Patient preferences for health states related to HPV infection: Visual analogue scales vs. time trade-off elicitation. Proceedings of the 21st International Papillomavirus Conference, Abstract No. 390.2 2004. Mexico City, Mexico. 2004.
27. Insinga RP, Glass AG, Myers ER, Rush BB. 2007. Abnormal outcomes following cervical cancer screening: Event duration and health utility loss. Med Decis Making 27(4):414-22.
28. Gold MR, Franks P, McCoy KI, Fryback DG. 1998. Toward consistency in cost-utility analyses: Using national measures to create condition-specific values. Med Care 36(6):778-92.
29. Andersen BL. 1996. Stress and quality of life following cervical cancer. J Nat Cancer Inst Monographs [21], 65-70.
30. Wenzel L, DeAlba I, Habbal R, Kluhsman BC, Fairclough D, Krebs LU, Anton-Culver H, Berkowitz R, Aziz N. 2005. Quality of life in long-term cervical cancer survivors. Gynecol Oncol 97(2):310-7.
31. Neumann PJ, Rosen AB, Weinstein MC. 2005. Medicare and cost-effectiveness analysis. N Engl J Med 353(14):1516-22.
32. Kulasingam SL, Myers ER. 2003. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290(6):781-9.
33. ACIP. ACIP Record of the Proceedings June 25-26, 2008. http://www.cdc.gov/vaccines/recs/acip/meetings.htm: accessed September 5, 2008.
34. Gold MR, Patrick DL, Torrance GW, et al., Identifying and valuing outcomes. In Gold MR, Patrick DL, Torrance GW, et al., Eds. Cost-effectiveness in health and medicine Ch. 4, Oxford University Press. 1996.